For example, vandetanib, a drug used in RET-dependent medullary thyroid cancer (MTC), has a broad range of kinase targets that include RET, VEGFR, etc. [7]; pre-clinical studies suggest that some of these secondary targets can contribute to drug efficacy (e. Here, KDR is linked to medullary thyroid gland carcinoma.